Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
17
NBIO Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
-14.96%
Day range:
$0.0002 - $0.0002
52-week range:
$0.0000 - $0.1345
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.9K
Avg. volume:
41.2K
1-year change:
-99.6%
Market cap:
$34.4K
Revenue:
--
EPS (TTM):
-$0.01
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Nascent Biotech, Inc. has -- downside to fair value with a price target of -- per share.
NBIO vs. S&P 500
-
Over the past 5 trading days, Nascent Biotech, Inc. has underperformed the S&P 500 by -78.09% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nascent Biotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nascent Biotech, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nascent Biotech, Inc. reported revenues of --.
Earnings Growth
-
Nascent Biotech, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Nascent Biotech, Inc. reported earnings per share of -$0.00.
Enterprise value:
91.6K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1M | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$924.9K | -$2.4M | -$1.5M | -$837.5K | -$251.2K | |
| EBITDA | -$924.9K | -$2.4M | -$1.5M | -$837.5K | -$251.2K | |
| Diluted EPS | -$0.01 | -$0.02 | -$0.01 | -$0.01 | -$0.00 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $99.2K | $105.4K | $1.2M | $1M | $181.8K | |
| Total Assets | $99.2K | $105.4K | $1.2M | $1M | $181.8K | |
| Current Liabilities | $910.2K | $1.2M | $2.4M | $1M | $945.5K | |
| Total Liabilities | $910.2K | $1.2M | $2.4M | $1M | $945.5K | |
| Total Equity | -$811K | -$1M | -$1.2M | -$6.4K | -$763.7K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$585.5K | -$1.5M | -$1.1M | -$341.5K | -$45.6K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $1.7M | $1.3M | $50K | $1.3M | -- | |
| Free Cash Flow | -$585.4K | -$1.5M | -$1.1M | -$341.5K | -$45.6K | |
NBIO
Sector
Market Cap
$34.4K
--
Price % of 52-Week High
0.15%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
-99.61%
--
Beta (5-Year)
1.550
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0007
200-day SMA
Sell
Level
$0.0036
Bollinger Bands (100)
Sell
Level
-0.0048 - 0.0152
Chaikin Money Flow
Buy
Level
28.2M
20-day SMA
Sell
Level
$0.0021
Relative Strength Index (RSI14)
Sell
Level
43.5366
ADX Line
Buy
Level
35.9649
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$0.0051
MACD (12, 26)
Sell
Level
-0.0018
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Sell
Level
-1.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. It focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Its products include Pritumumab, CLNH5, and MultiPharm. The company was founded by Mark C. Glassy on March 3, 2014 and is headquartered in North Palm Beach, FL.
Stock Forecast FAQ
In the current month, NBIO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NBIO average analyst price target in the past 3 months is --.
-
Where Will Nascent Biotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nascent Biotech, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Nascent Biotech, Inc.?
Analysts are divided on their view about Nascent Biotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nascent Biotech, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Nascent Biotech, Inc.'s Price Target?
The price target for Nascent Biotech, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nascent Biotech, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NBIO?
You can purchase shares of Nascent Biotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nascent Biotech, Inc. shares.
-
What Is The Nascent Biotech, Inc. Share Price Today?
Nascent Biotech, Inc. was last trading at $0.0000 per share. This represents the most recent stock quote for Nascent Biotech, Inc.. Yesterday, Nascent Biotech, Inc. closed at $0.0002 per share.
-
How To Buy Nascent Biotech, Inc. Stock Online?
In order to purchase Nascent Biotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NBIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NBIO
Sector
P/E ratio
--
--
PEG ratio
--
--
P/B ratio
--
--
Price / LTM sales
--
--
Growth Metrics
NBIO
Sector
Revenue growth
--
--
Earnings growth
--
--
Revenue (5-year growth)
--
--
Earnings forecast
--
--
Profitability
NBIO
Sector
Profitability FY 2025
--
--
Return on invested capital
--
--
Return on assets
--
--
Return on equity
--
--
Earnings Date
Last Earnings Date
Dec
26
Next Earnings Date
Dec
26
Estimated Next Earnings Date
Mar
27
Balance Sheet
NBIO
Sector
Total cash
$47.4K
--
Short term investments
--
--
Total assets
$552.1K
--
Long term debt
--
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
